<DOC>
	<DOCNO>NCT00968981</DOCNO>
	<brief_summary>This two stage , Phase Ib study design describe pharmacokinetics GDC-0449 patient advance solid tumor refractory treatment standard therapy exists .</brief_summary>
	<brief_title>A Study Hedgehog Pathway Inhibitor GDC-0449 Patients With Locally Advanced Metastatic Solid Tumors That Are Refractory Standard Therapy Whom No Standard Therapy Exists</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Histologically document , incurable , locally advanced metastatic solid malignancy progress firstline secondline therapy ( secondline therapy show provide clinical benefit ) ; patient basal cell carcinoma exclude study unless qualify another open GDC0449 clinical trial For patient disease evaluable physical examination , diagnosis must also include biomarker confirmation Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Documented negative pregnancy test woman childbearing potential agreement use effective form contraception duration study Adequate hematopoietic capacity Adequate hepatic function Adequate renal function At least 3 week since last chemotherapy , investigational agent , radiation therapy , major surgical procedure recovery pretreatment baseline stabilization treatmentrelated toxicity Exclusion Criteria Known , untreated central nervous system ( CNS ) malignancy treat brain metastasis radiographically stable â‰¥ 3 month Active infection require intravenous ( IV ) antibiotic Clinically significant history liver disease , include cirrhosis , current alcohol abuse , current know active infection hepatitis Any medical condition diagnosis would likely impair absorption orally administer drug ( e.g. , gastrectomy , ileal bypass , chronic diarrhea , gastroparesis ) Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication Pregnant lactate Treatment exclude medication , include strong CYP450 inhibitor inducer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hedgehog</keyword>
	<keyword>BCC</keyword>
	<keyword>basal cell carcinoma</keyword>
</DOC>